Tonix Pharmaceuticals Announces Oral Presentation at the World Antiviral Congress
November 21, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., Chief...
Tonix Pharmaceuticals Announces Data from an in vitro Study of the Impact of Oxytocin on Human Neurons at Neuroscience 2022, the Annual Meeting of the Society for Neuroscience
November 16, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced data describing the impact of...
Tonix Pharmaceuticals Announces Poster Presentation at Neuroscience 2022 by the Society for Neuroscience
November 09, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced a poster presentation by an academic...
Tonix Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights
November 07, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Five Potentially Pivotal Phase 2 or 3 Studies for CNS Programs Expected to be in the Clinic by First Quarter 2023 Data from Planned Interim Analyses of TNX-102 SL in Phase 3 Fibromyalgia Study...
Tonix Pharmaceuticals to Present at the 2022 BioFuture Conference
October 31, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Jessica Morris, Chief Operating...
Tonix Pharmaceuticals Announces Pricing of $15 Million Private Placement of Convertible Redeemable Preferred Stock
October 25, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities...
Tonix Pharmaceuticals to Present at the 2022 ThinkEquity Conference
October 19, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Jessica Morris, Chief Operating...
Tonix Pharmaceuticals to Participate in the 2022 BIO-Europe Conference
October 17, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., Chief...
Tonix Pharmaceuticals Announces IND Clearance for TNX-601 ER as a Potential Treatment for Major Depressive Disorder
October 03, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
TNX-601 ER, Tianeptine Hemioxalate, is an Extended-Release Tablet for Once-a-Day Dosing Phase 2 Clinical Trial of TNX-601 ER Expected to Start First Quarter 2023 CHATHAM, N.J., Oct. 03, 2022 ...
Tonix Pharmaceuticals Presents Data from Retrospective Observational Database Study on the Incidence of Multi-Site Pain Symptoms in Long COVID Patients at IASP 2022 World Congress on Pain
September 22, 2022 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Approximately 40% of Long COVID Patients Experience Multi-Site Pain Similar to Overlapping Chronic Pain Syndromes Fibromyalgia and ME/CFS Approximately 50% of Long COVID Patients with Multi-Site Pain...